Vitamin B12 marketed by Vitruvias Therapeutics under NDC Code 69680-112-01 NDC Code(s) : 69680-112-01, 69680-112-25, 69680-112-10, 69680-113-10, 69680-113-99, 69680-121-05, 69680-121-30, 69680-121-10 Packager : Vitruvias Therapeutics Category : HUMAN PRESCRIPTION DRUG LABEL DEA Schedule : none Marketing Status : New Drug Application INGREDIENTS AND APPEARANCE LABELER - Vitruvias Therapeutics(079200795) PRINCIPAL DISPLAY PANEL Cyanocobalamin Injection, USP 1000 mcg/mL NDC 6968011210 10 x 1 mL VIALS For Intramuscular or Subcutaneous Use Only Each mL contains: Cyanocobalamin 1000 mcg, Sodium Chloride 0.9%, Benzyl Alcohol 1.5%, Water for Injection q.s
[6] [7] Common neurological presentations include: Peripheral neuropathy tingling, numbness, or pins-and-needles sensations (paraesthesia), typically beginning in the feet and hands in a symmetrical 'glove and stocking' distribution Gait disturbances unsteadiness, difficulty walking, or loss of balance due to proprioceptive impairment Cognitive changes memory problems, confusion, difficulty concentrating, or 'brain fog' Mood alterations depression, irritability, or personality changes Weakness muscle weakness or fatigue affecting daily activities Visual disturbances rarely, optic neuropathy causing blurred or reduced vision In more severe cases, patients may develop subacute combined degeneration of the spinal cord , a serious condition affecting the posterior and lateral columns
A standard U-100 insulin syringe has markings from 0 to 100 units
Dizziness and Fatigue : Anecdotal reports from human users document episodes of dizziness and fatigue following peptide administration
